Tobira Combination Therapy Shows Positive Results

The Phase I study assessed the pharmacokinetics, safety and tolerability of cenicriviroc and tenofovir disoproxil fumarate when co-administered in healthy adults.

Tobira Therapeutics, a biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease, has received promising results in healthy adults from its Phase I study of cenicriviroc in combination with tenofovir disoproxil fumarate.

Cenicriviroc is a potent antagonist of CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor involved in the inflammation process.

The open-label, single-dose, randomised, cross-over Phase I study assessed the pharmacokinetics, safety and tolerability of cenicriviroc and tenofovir disoproxil fumarate when co-administered in healthy adults.

Drug development / regu